Clinical trial on Post covid fibrosis and idiopathic pulmonary fibrosis.

A prospective open label study to evaluate the efficacy and safety of FIBROTAC Capsules in Post Covid Fibrosis and Idiopathic Pulmonary Fibrosis

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035430

Enrollment

Registered

2021-08-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: fibrotac capsules: Dose : 440 mg Dosage : Capsules twice daily Duration :12 weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients between age 18years and 70 years. 2) One month after COVID 19 infection. 3) RTPCR positive cases. 4) Symptomatic and radiological evidence of POST COVID pulmonary fibrosis( PCILD).

Exclusion criteria

Exclusion criteria: 1) Pregnant women, lactating mother 2) Renal failure 3) Hepatic failure 4) Critically ill patients

Design outcomes

Primary

Measure	Time frame
1. Improvement in 6minutes walk distance after 3 months of therapy. 2. Subjective improvement in dyspnea and cough Timepoint: Day 0 to week 12	—

Secondary

Measure	Time frame
Improvement in pulmonary function test and DLCOTimepoint: Day 0 to week 12	—

Countries

India

Contacts

Public ContactDrAnandha Kumar

Head of theDepartment of Pulmonary Medicine, Sooriya Hospital

venu.sooriya@gmail.com04423761751

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026